EPS: As of FY2025 Q2, the actual value is USD -0.41.

EBIT: As of FY2025 Q2, the actual value is USD -17.92 M.

Segment Revenue

• No revenue has been earned as of June 30, 2025.

Operational Metrics

• Net Loss: For the three months ended June 30, 2025, net loss was - $1,981,293 compared to - $96,923 for the same period in 2024, reflecting an increase of - $1,884,370.
• General and Administrative Expenses: Increased to $395,692 for the three months ended June 30, 2025, from $86,423 for the same period in 2024, reflecting an increase of $309,269.
• Research and Development Expenses: Increased to $352,887 for the three months ended June 30, 2025, from $10,500 for the same period in 2024, reflecting an increase of $342,387.
• Sales and Marketing Expenses: Increased to $51,311 for the three months ended June 30, 2025, from $0 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $2,891,838 for the six months ended June 30, 2025, compared to - $249,215 for the same period in 2024.
• Net Cash Provided by Financing Activities: $3,094,438 for the six months ended June 30, 2025, compared to $257,645 for the same period in 2024.

Unique Metrics

• Convertible Notes: The fair value of convertible notes at June 30, 2025, was $3,617,508.

Future Outlook and Strategy

• Core Business Focus: Aspire plans to generate revenue through developing and marketing drugs and nutraceuticals using novel sublingual delivery technology. The company expects to commence commercialization activities by building a focused sales and marketing organization in the United States to sell its products, subject to receiving marketing approvals.
• Non-Core Business: Aspire is exploring licensing possibilities for its sublingual melatonin sleep-aid product and has developed formulations for sublingually administered vitamins and testosterone, with plans for clinical testing and NDA submissions.

Priority

• Aspire plans to seek FDA 505(b)(2) Fast Track designation for its prescription strength high dose aspirin product in 2025.